Mouse Anti-LAG3 Recombinant Antibody (CBYY-C2631) (CBMAB-C4072-YY)

Name: Mouse Anti-LAG3 Recombinant Antibody (CBYY-C2631)
SKU: CBMAB-C4072-YY
Rating: 5 (1 reviews)

See all LAG3 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBYY-C2631

Application

Immunogen

Mouse myeloma cell line NS0-derived recombinant human LAG-3 Leu23-Leu450

Specificity

Human

Antibody Isotype

IgG2a

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Buffer

0.5 mg/mL

Preservative

PBS, 5% trehalose

Concentration

Liquid

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

lymphocyte activating 3

Entrez Gene ID

3902

UniProt ID

P18627

Alternative Names

MET Proto-Oncogene, Receptor Tyrosine Kinase; Hepatocyte Growth Factor Receptor; Tyrosine-Protein Kinase Met; Scatter Factor Receptor; Proto-Oncogene C-Met; HGF/SF Receptor; HGF Receptor; SF Receptor; EC 2.7.10.1;

Function

Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity).
FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity).
Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).
May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity).
Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity).
Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).
Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185).
Secreted lymphocyte activation gene 3 protein
May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.

Biological Process

Adaptive immune responseIEA:UniProtKB-KW
Cell surface receptor signaling pathwayISS:UniProtKB
Negative regulation of interleukin-2 productionIEA:Ensembl
Negative regulation of regulatory T cell differentiationISS:UniProtKB
Plasmacytoid dendritic cell activationISS:UniProtKB
Positive regulation of natural killer cell mediated cytotoxicityIEA:Ensembl
Regulation of immune responseISS:UniProtKB

Cellular Location

Lymphocyte activation gene 3 protein:
Cell membrane
Secreted lymphocyte activation gene 3 protein:
Secreted
Produced following cleavage of the main chain.

Topology

Extracellular: 23-450
Helical: 451-471
Cytoplasmic: 472-525

PTM

Lymphocyte activation gene 3 protein
Proteolytically cleaved by ADAM10 and ADAM17 within the connecting peptide region, leading to release of Secreted lymphocyte activation gene 3 protein (sLAG-3). ADAM10 mediates constitutive cleavage, but cleavage increases following T-cell activation, whereas shedding by ADAM17 is induced by TCR signaling in a PRKCQ-dependent manner.

Zhao, L., Wang, H., Xu, K., Liu, X., & He, Y. (2022). Update on lymphocyte-activation gene 3 (LAG-3) in cancers: From biological properties to clinical applications. Chinese Medical Journal, 135(10), 1203-1212.

Lythgoe, M. P., Liu, D. S. K., Annels, N. E., Krell, J., & Frampton, A. E. (2021). Gene of the month: Lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 74(9), 543-547.

Slevin, S. M., Garner, L. C., Lahiff, C., Tan, M., Wang, L. M., Ferry, H., ... & Keshav, S. (2020). Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis. Journal of Crohn's and Colitis, 14(10), 1446-1461.

Gebauer, F., Krämer, M., Bruns, C., Schlößer, H. A., Thelen, M., Lohneis, P., ... & Quaas, A. (2020). Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. Journal of cancer research and clinical oncology, 146, 2319-2327.

Atkinson, V., Khattak, A., Haydon, A., Eastgate, M., Roy, A., Prithviraj, P., ... & Triebel, F. (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for immunotherapy of cancer, 8(2).

Yu, X., Huang, X., Chen, X., Liu, J., Wu, C., Pu, Q., ... & Zhou, L. (2019, August). Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. In MAbs (Vol. 11, No. 6, pp. 1139-1148). Taylor & Francis.

Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2019, April). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. In Seminars in immunology (Vol. 42, p. 101305). Academic Press.

Saleh, R. R., Peinado, P., Fuentes-Antrás, J., Pérez-Segura, P., Pandiella, A., Amir, E., & Ocaña, A. (2019). Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Frontiers in oncology, 9, 1040.

Zhang, Y., Liu, Y. D., Luo, Y. L., Liu, B. L., Huang, Q. T., Wang, F., & Zhong, Q. (2018). Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma. Journal of Cancer, 9(22), 4287.

Wang, Y., Dong, T., Xuan, Q., Zhao, H., Qin, L., & Zhang, Q. (2018). Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer. Journal of breast cancer, 21(2), 124-133.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-LAG3 Recombinant Antibody (CBYY-C2631)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-LAG3 Recombinant Antibody (CBWJC-4106) (CAT#: CBMAB-C5448WJ)

Mouse Anti-LAG3 Recombinant Antibody (CBYJL-1048) (CAT#: CBMAB-L0469-YJ)

Mouse Anti-LAG3 Recombinant Antibody (11E3) (CAT#: CBMAB-L0468-YJ)

Rabbit Anti-Lag3 Recombinant Antibody (CBYJL-1058) (CAT#: CBMAB-L0485-YJ)

Mouse Anti-LAG3 Recombinant Antibody (CBT4415) (CAT#: V2LY-0625-LY1011)

Rat Anti-LAG3 Recombinant Antibody (AG131) (CAT#: V2LY-0524-LY89)

Mouse Anti-LAG3 Recombinant Antibody (8G6) (CAT#: CBMAB-L0478-YJ)

Mouse Anti-LAG3 Recombinant Antibody (CBYJL-1057) (CAT#: CBMAB-L0484-YJ)

Mouse Anti-LAG3 Recombinant Antibody (17B4) (CAT#: CBMAB-L0470-YJ)

Mouse Anti-LAG3 Recombinant Antibody (CBYJL-1056) (CAT#: CBMAB-L0483-YJ)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry